Zentalis Pharmaceuticals
ZNTL
136 hedge funds and large institutions have $261M invested in Zentalis Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 45 increasing their positions, 40 reducing their positions, and 35 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
13% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 40
6% less funds holding
Funds holding: 145 → 136 (-9)
8.17% less ownership
Funds ownership: 107.96% → 99.8% (-8.2%)
17% less capital invested
Capital invested by funds: $314M → $261M (-$53.1M)
18% less call options, than puts
Call options by funds: $352K | Put options by funds: $431K
26% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.51M |
| 2 |
AC
Almitas Capital
Santa Monica,
California
|
+$3.49M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
+$3.46M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.23M |
| 5 |
Millennium Management
New York
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.56M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$6.49M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$5.42M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.79M |
ZNTL Hedge Fund Activity: Q3 2024 in Review
136 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q3 2024, worth a combined $261M — down 17% from $314M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of ZNTL and 26 opened new positions — a net loss of 9 holders — while 40 trimmed existing stakes and 45 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $3.51M. The largest seller was Fidelity Investments, cutting an estimated $13.1M.
- 136 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q3 2024, down from 145 in Q2 2024.
- Funds reported $261M of Zentalis Pharmaceuticals stock for Q3 2024, down 17% quarter-over-quarter.
- 26 funds opened new Zentalis Pharmaceuticals positions in Q3 2024 and 35 closed out, a net change of -9 holders.
- The largest Zentalis Pharmaceuticals buyer in Q3 2024 was Opaleye Management, an estimated $3.51M added.
- The largest Zentalis Pharmaceuticals seller in Q3 2024 was Fidelity Investments, an estimated $13.1M sold.
Based on aggregated 13F filings for Q3 2024.